Managing Skin Rash During EGFR-Targeted Therapy for Cancer
Author Information
Author(s): Barbara Melosky, R. Burkes, D. Rayson, T. Alcindor, N. Shear, M. Lacouture
Primary Institution: BC Cancer Agency
Hypothesis
Can proactive management improve outcomes for patients experiencing skin rash from EGFR-targeted monoclonal antibody treatment?
Conclusion
A proactive, multidisciplinary approach to managing skin rash can improve patient quality of life and treatment outcomes.
Supporting Evidence
- Skin rash is a common side effect of EGFR-targeted therapies, affecting 80%-90% of patients.
- Proactive management can reduce the incidence of severe skin toxicities by more than 50%.
- Patients with skin rash during treatment may have better clinical outcomes.
Takeaway
When people take certain cancer medicines, they can get rashes on their skin. Taking care of the skin early can help make the medicine work better and make people feel better.
Methodology
The article reviews existing recommendations and consensus documents on managing skin rash associated with EGFR inhibitors.
Limitations
The recommendations are based on qualitative evidence and anecdotal experience rather than well-controlled randomized clinical trials.
Statistical Information
P-Value
p<0.0001
Confidence Interval
95% CI: 0.44 to 0.66
Want to read the original?
Access the complete publication on the publisher's website